Different probiotic supplementations for side effects prevention in a standard anti-H. pylori scheme: a randomized, double-blind, placebo-controlled study

2001 ◽  
Vol 96 (9) ◽  
pp. S51
Author(s):  
F CREMONINI
Keyword(s):  
Side Effects ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
H Pylori

scholarly journals Failure of a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of H. pylori Eradication in H. pylori-Infected Patients with Functional Dyspepsia

Gut and Liver ◽  
2011 ◽  
Vol 5 (4) ◽  
pp. 468-471 ◽  
Author(s):  
Su Jin Hong ◽  
In Kyung Sung ◽  
Jae Gyu Kim ◽  
Sang Woo Lee ◽  
Suck Chei Choi ◽  
...  
Keyword(s):  
Functional Dyspepsia ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
H Pylori

scholarly journals Effects of Piracetam as an Adjuvant Therapy on Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

2021 ◽  
Vol 15 (2) ◽  
Author(s):  
Kaveh Alavi ◽  
Elham Shirazi ◽  
Maryam Akbari ◽  
Zahra Shahrivar ◽  
Fatemeh-Sadat Noori ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Placebo Group ◽  
Side Effects ◽  
Adjuvant Therapy ◽  
Attention Deficit ◽  
Controlled Study ◽  
Double Blind ◽  
Children With Adhd ◽  
Double Blind Placebo ◽  
Hyperactivity Disorder

Background: Stimulants are highly effective in controlling symptoms of Attention-deficit/hyperactivity disorder (ADHD), but 30% of individuals with ADHD do not respond to them or cannot tolerate their side effects; thus, alternative treatment approaches need to be considered. Objectives: To evaluate the effect and safety of piracetam as an adjuvant therapy plus methylphenidate (MPH) in children with ADHD. Methods: Thirty-six children with ADHD (6-16 years old), admitted to three academic outpatient child psychiatric clinics in the second half of 2015, were randomly assigned to the “methylphenidate plus piracetam group” and the “methylphenidate plus placebo” group, in a double-blind, placebo-controlled study, for 6 weeks. The “Conner’s Parents’ Rating Scale-Revised (CPRS-R), Children Symptom Inventory-4 (CSI-4), Clinical Global Impression-Improvement scale (CGI-I), and Children’ Global Assessment Scale (CGAS) were completed at baseline and at the ends of the third and the sixth week, and the New York State Psychiatric Institute side effect forms were completed weekly, as outcome measures. Results: The level of improvement in CPRS-R, CSI-4, and CGI-I scales were significantly higher in the “methylphenidate plus piracetam” group compared with the “methylphenidate plus placebo” group. Side effects were not remarkable in any group. Conclusions: Piracetam as a short-term adjuvant treatment to methylphenidate can have considerable therapeutic effect and safety profile in children with ADHD and deserves further exploration to assess its potentialities in ADHD treatment.

scholarly journals Efficacy of acamprosate in the treatment of alcohol-dependent outpatients

2003 ◽  
Vol 25 (3) ◽  
pp. 156-159 ◽  
Author(s):  
Danilo Antonio Baltieri ◽  
Arthur Guerra de Andrade
Keyword(s):  
Side Effects ◽  
Alcohol Dependence ◽  
Placebo Treatment ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Continuous Abstinence ◽  
Icd 10 ◽  
Alcohol Dependent

OBJECTIVE: To evaluate the efficacy and security of acamprosate in the treatment of 75 men, aged 18 to 59 years, with diagnosis of alcohol dependence according to the ICD-10. METHODS: Double-blind, placebo-controlled study, 24-week long. After a one-week detoxification period, patients were randomly divided in two groups: the first group received acamprosate (six tablets of 333 mg/d for 12 weeks) and the second group received placebo (six tablets for 12 weeks). After the first 12 weeks, patients continued the follow-up for further 12 weeks without medication. RESULTS: Patients who were receiving acamprosate showed significantly higher continuous abstinence time within the 24 weeks of treatment compared with patients who were assigned to placebo treatment (p=.017). Twenty-five percent of patients who were receiving acamprosate and 20% of the placebo-treated patients dropped out. Few side-effects were reported in both groups. CONCLUSION: Acamprosate proved to be safe and effective in treating alcohol-dependent patients and to maintain the abstinence during 24 weeks.

Impact of bacillus clausii supplementation on anti Helicobacter pylori therapy related side effects: A randomized double blind placebo controlled study

2003 ◽  
Vol 124 (4) ◽  
pp. A361
Author(s):  
Enrico C. Nista ◽  
Immacolata A. Cazzato ◽  
Marcello Candelli ◽  
Francesco Franceshi ◽  
Lucia Fini ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Side Effects ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Bacillus Clausii

Comparison of Propranolol LA 80 mg and Propranolol LA 160 mg in Migraine Prophylaxis: A Placebo Controlled Study

Cephalalgia ◽  
1993 ◽  
Vol 13 (2) ◽  
pp. 128-131 ◽  
Author(s):  
Hisham K Al-Qassab ◽  
Leslie J Findley
Keyword(s):  
Side Effects ◽  
Migraine Prophylaxis ◽  
Controlled Study ◽  
Headache Frequency ◽  
Double Blind ◽  
Once Daily ◽  
Double Blind Placebo ◽  
Headache Severity ◽  
Negative Effect ◽  
Long Acting

Thirty patients with severe classical and common migraine participated in a double-blind placebo-con-trolled cross-over study of migraine prophylaxis with propranolol LA (long-acting) 80 mg once daily, or propranolol LA 160 mg once daily or placebo. Each treatment was given for two months. There were no significant differences between the three treatment periods in headache frequency, headache severity, nausea frequency or severity. There was a non-significant trend for reduced duration of headache with the two doses of propranolol. The possible reasons for this negative effect are discussed. The safety of propranolol and its lack of serious side effects were demonstrated.

scholarly journals The side-effects of different doses of iron sulfate on women of reproductive age: a randomized double-blind, placebo-controlled study

2011 ◽  
Vol 11 (3) ◽  
pp. 275-281 ◽  
Author(s):  
Katia Maria de Melo Machado ◽  
Luiz Oscar Cardoso Ferreira ◽  
Ariani Impieri de Souza ◽  
Alcides da Silva Diniz
Keyword(s):  
Side Effects ◽  
Controlled Trial ◽  
Reproductive Age ◽  
Iron Sulfate ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Main Complaint ◽  
Gastrointestinal Side Effects ◽  
Different Doses

OBJECTIVES: to identify side effects of the use of different doses of iron sulfate (IS). METHODS: an eight-week randomized, double blind, placebo-controlled trial was carried out involving 727 women aged 20-49 years between October 2005 and October 2006. The women were randomly allocated into eight groups with daily or twice-weekly doses administered during or in between meals. The information was obtained by weekly telephone contact. Analysis involved comparison of the proportion of complaints from the different groups. RESULTS: of 726 women initially selected, 74.2% completed eight weeks of follow up. In the regimens containing IS 95.2% of women reported gastrointestinal complaints. More complaints were reported for daily doses than for ones (p <0.001). Those taken between meals were associated with more nausea than those taken during meals (p<0.001). Of the 95 women who withdrew from the experiment, 88.4% belonged to the IS group and diarrhea was the main complaint (29.8%). CONCLUSIONS: the use of iron sulfate was associated with gastrointestinal side effects, especially when taken daily and diarrhea was the main complaint associated with IS.

Sign in / Sign up

Export Citation Format

Share Document